Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 8, 2025 • 11:00 PM ET

Date/Time Source News Release
05/28/2025 07:00 AM EDT GlobeNewswire Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split
05/13/2025 08:30 AM EDT GlobeNewswire Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia
05/12/2025 08:30 AM EDT GlobeNewswire Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision
04/23/2025 08:30 AM EDT GlobeNewswire Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference
04/09/2025 08:58 AM EDT GlobeNewswire Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial
04/07/2025 04:30 PM EDT GlobeNewswire Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit
03/27/2025 08:30 AM EDT GlobeNewswire Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress
03/18/2025 05:33 PM EDT GlobeNewswire Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K
03/06/2025 09:30 AM EST GlobeNewswire Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)
02/25/2025 08:30 AM EST GlobeNewswire Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment
Page

Additional News

As of June 8, 2025 • 11:00 PM ET

Date/Time Source News Release
06/04/2025 02:00 PM EDT PRISM News PRISM Mid-Day Movers: MedDevices Index Strengthens on Expanded European Footprint for Robotic Hernia Repair
06/02/2025 02:00 PM EDT PRISM News PRISM Mid-Day Movers: AI Infrastructure and Pharma Indices Jump On Lease Deal and Trial Results
05/28/2025 01:30 PM EDT PRISM News PRISM Mid-Day Movers: Weight Loss Innovation and Warrant Cancellation Drive Market Action
05/28/2025 09:00 AM EDT BioMedWire BioMedNewsBreaks - Oragenics Inc. (NYSE American: OGEN) Sets 1-for-30 Reverse Stock Split Effective June 3 
05/28/2025 07:17 AM EDT SeekingAlpha Oragenics announces 1-for-30 reverse stock split
05/13/2025 09:45 AM EDT InvestorWire InvestorNewsBreaks - Oragenics Inc. (NYSE American: OGEN) Secures Australian Approval to Launch Phase II Concussion Trial
05/12/2025 09:15 AM EDT InvestorWire InvestorNewsBreaks - Oragenics Inc. (NYSE American: OGEN) to Host May 20 Webinar on Concussion Drug Program ONP-002
04/09/2025 09:45 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Oragenics Inc. (NYSE American: OGEN) Submits Protocol for Phase II Concussion Trial in New Zealand
04/08/2025 09:15 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Oragenics Inc. (NYSE American: OGEN) Highlights Intranasal Drug Delivery at Boston Summit
03/27/2025 09:55 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Oragenics Inc. Highlights Q1 Milestones and Prepares for Concussion Drug Trial
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.